PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.92%
Both companies show declining cash positions (-42.92% vs AVXL's -11.22%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-42.83%
Cash + STI yoy ≥ 1.5x AVXL's -11.22%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.38%
≥ 1.5x AVXL's -10.34%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-9.44%
Below half AVXL's 28.33%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.57%
Below half of AVXL's -99.80%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
≥ 1.5x AVXL's -21.05%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
31.92%
Less than half of AVXL's -26.95%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.79%
Exceeding 1.5x AVXL's -11.79%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-7.19%
Less than half of AVXL's -24.32%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.19%
Less than half of AVXL's 275.85%. David Dodd sees far fewer liability expansions relative to competitor.
1.19%
Less than half of AVXL's 23.37%. David Dodd sees fewer share issuances vs. competitor.
-6.33%
Below half AVXL's -22.62%. Michael Burry suspects major net losses or high dividends vs. competitor.
-55.74%
Above 1.5x AVXL's -33.33%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
-181.05%
≥ 1.5x AVXL's -97.40%. David Dodd sees stronger capital base growth than competitor.
-39.92%
≥ 1.5x AVXL's -21.05%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.34%
50-75% of AVXL's 83.07%. Bruce Berkowitz notes comparatively lower net debt expansion.